198 related articles for article (PubMed ID: 34594424)
1. Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab.
Kamiimabeppu D; Osumi H; Shinozaki E; Ooki A; Wakatsuki T; Yoshino K; Sato T; Nakayama I; Ogura M; Takahari D; Chin K; Yamaguchi K
Oncol Lett; 2021 Nov; 22(5):783. PubMed ID: 34594424
[TBL] [Abstract][Full Text] [Related]
2. Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study.
Nose Y; Kagawa Y; Hata T; Mori R; Kawai K; Naito A; Sakamoto T; Murakami K; Katsura Y; Ohmura Y; Masuzawa T; Takeno A; Takeda Y; Kato T; Murata K
Cancer Chemother Pharmacol; 2020 Sep; 86(3):427-433. PubMed ID: 32816155
[TBL] [Abstract][Full Text] [Related]
3. Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis.
Yoshino T; Taieb J; Kuboki Y; Pfeiffer P; Kumar A; Hochster HS
Ther Adv Med Oncol; 2023; 15():17588359221146137. PubMed ID: 36743525
[TBL] [Abstract][Full Text] [Related]
4. RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer.
Koumarianou A; Ntavatzikos A; Symeonidis D; Vallilas C; Giannakakou M; Papaxoinis G; Xynogalos S; Boukovinas I; Demiri S; Kampoli K; Oikonomopoulos G; Samantas E; Res E; Androulakis N; Vourli G; Souglakos I; Karamouzis M
Biomedicines; 2023 Apr; 11(5):. PubMed ID: 37238938
[TBL] [Abstract][Full Text] [Related]
5. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials.
Yoshino T; Cleary JM; Van Cutsem E; Mayer RJ; Ohtsu A; Shinozaki E; Falcone A; Yamazaki K; Nishina T; Garcia-Carbonero R; Komatsu Y; Baba H; Argilés G; Tsuji A; Sobrero A; Yamaguchi K; Peeters M; Muro K; Zaniboni A; Sugimoto N; Shimada Y; Tsuji Y; Hochster HS; Moriwaki T; Tran B; Esaki T; Hamada C; Tanase T; Benedetti F; Makris L; Yamashita F; Lenz HJ
Ann Oncol; 2020 Jan; 31(1):88-95. PubMed ID: 31912801
[TBL] [Abstract][Full Text] [Related]
6. Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan.
Kagawa Y; Shinozaki E; Okude R; Tone T; Kunitomi Y; Nakashima M
ESMO Open; 2023 Aug; 8(4):101614. PubMed ID: 37562196
[TBL] [Abstract][Full Text] [Related]
7. Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial.
Oki E; Makiyama A; Miyamoto Y; Kotaka M; Kawanaka H; Miwa K; Kabashima A; Noguchi T; Yuge K; Kashiwada T; Ando K; Shimokawa M; Saeki H; Akagi Y; Baba H; Maehara Y; Mori M
Cancer Med; 2021 Jan; 10(2):454-461. PubMed ID: 33249761
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7.
Takahashi T; Yamazaki K; Oki E; Shiozawa M; Mitsugi K; Makiyama A; Nakamura M; Ojima H; Kagawa Y; Matsuhashi N; Okuda H; Asayama M; Yuasa Y; Shimada Y; Manaka D; Watanabe J; Oba K; Yoshino T; Yoshida K; Maehara Y
ESMO Open; 2021 Apr; 6(2):100093. PubMed ID: 33744811
[TBL] [Abstract][Full Text] [Related]
9. Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.
Kuboki Y; Terazawa T; Masuishi T; Nakamura M; Watanabe J; Ojima H; Makiyama A; Kotaka M; Hara H; Kagawa Y; Sugimoto N; Kawakami H; Takashima A; Kajiwara T; Oki E; Sunakawa Y; Ishihara S; Taniguchi H; Nakajima TE; Morita S; Shirao K; Takenaka N; Ozawa D; Yoshino T
Br J Cancer; 2023 May; 128(10):1897-1905. PubMed ID: 36871043
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review.
Shitara K; Falcone A; Fakih MG; George B; Sundar R; Ranjan S; Van Cutsem E
Oncologist; 2024 May; 29(5):e601-e615. PubMed ID: 38366864
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab mitigates codon-specific effects of trifluridine/tipiracil on efficacy outcome parameters in metastatic colorectal cancer.
Doleschal B; Taghizadeh H; Lentner T; Riedl JM; Granitzer J; Morariu D; Decker J; Aichberger KJ; Webersinke G; Kirchweger P; Petzer A; Rumpold H
ESMO Open; 2023 Dec; 8(6):102064. PubMed ID: 37977001
[TBL] [Abstract][Full Text] [Related]
12. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer.
Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS
Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008
[No Abstract] [Full Text] [Related]
13. Trifluridine/tipiracil with and without ramucirumab for advanced gastric cancer: a comparative observational study.
Narita Y; Ogata T; Ishizuka Y; Sakakida T; Wakabayashi M; Kodama H; Honda K; Masuishi T; Taniguchi H; Kadowaki S; Ando M; Tajika M; Muro K
Sci Rep; 2024 Jun; 14(1):12658. PubMed ID: 38830895
[TBL] [Abstract][Full Text] [Related]
14. Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center.
Patel AK; Abhyankar R; Brais LK; Duh MS; Barghout VE; Huynh L; Yenikomshian MA; Ng K; Fuchs CS
Oncologist; 2021 Dec; 26(12):e2161-e2169. PubMed ID: 34406678
[TBL] [Abstract][Full Text] [Related]
15. Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G).
Kito Y; Kawakami H; Mitani S; Nishina S; Matsumoto T; Tsuzuki T; Shinohara Y; Shimokawa H; Kumanishi R; Ohta T; Katsuya H; Kawakami T; Nishina T; Hasegawa H; Akiyoshi K; Chiba Y; Yamazaki K; Hironaka S; Muro K
Oncologist; 2024 Mar; 29(3):e330-e336. PubMed ID: 37950903
[TBL] [Abstract][Full Text] [Related]
16. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
Prager GW; Taieb J; Fakih M; Ciardiello F; Van Cutsem E; Elez E; Cruz FM; Wyrwicz L; Stroyakovskiy D; Pápai Z; Poureau PG; Liposits G; Cremolini C; Bondarenko I; Modest DP; Benhadji KA; Amellal N; Leger C; Vidot L; Tabernero J;
N Engl J Med; 2023 May; 388(18):1657-1667. PubMed ID: 37133585
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.
Kröning H; Göhler T; Decker T; Grundeis M; Kojouharoff G; Lipke J; Semsek D; Moorahrend E; Sauer A; Bruch HR; Liersch R; Nusch A; Vehling-Kaiser U; Welslau M; Grunewald R; Harich HD; Stephany M; Uhlig J; de Buhr R; Frank M; Hogrefe C; Marschner N; Potthoff K; Hartmann F; Reisländer T; Schwaner I
Int J Cancer; 2023 Sep; 153(6):1227-1240. PubMed ID: 37260368
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of Patients with Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil beyond the Second Line: A Multicenter Retrospective Study from Saudi Arabia.
Alghamdi M; Bazarbashi S; Mahrous M; Alshaer O; Mostafa Gad A; Aseafan M; Abdelgelil M; Alshabi RM; Alghanmi HA; Naser NA; Al Hariri H; ALHamad A; Al-Saleh K; Abdel-Aziz N; Elsamany S
J Oncol; 2022; 2022():3796783. PubMed ID: 36147443
[TBL] [Abstract][Full Text] [Related]
19. Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study.
Bordonaro R; Calvo A; Auriemma A; Hollebecque A; Rubovszky G; Saunders MP; Pápai Z; Prager G; Stein A; André T; Argilés G; Cubillo A; Dahan L; Edeline J; Leger C; Cattan V; Fougeray R; Amellal N; Tabernero J
ESMO Open; 2021 Oct; 6(5):100270. PubMed ID: 34547581
[TBL] [Abstract][Full Text] [Related]
20. Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
Van Cutsem E; Hochster H; Shitara K; Mayer R; Ohtsu A; Falcone A; Yoshino T; Doi T; Ilson DH; Arkenau HT; George B; Benhadji KA; Makris L; Tabernero J
ESMO Open; 2022 Dec; 7(6):100633. PubMed ID: 36455504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
